<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635296</url>
  </required_header>
  <id_info>
    <org_study_id>NP28023</org_study_id>
    <secondary_id>2011-006252-36</secondary_id>
    <nct_id>NCT01635296</nct_id>
  </id_info>
  <brief_title>A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia</brief_title>
  <official_title>A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and
      efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous
      leukemia. In Arm A, cohorts of previously untreated patients deemed unsuitable for standard
      induction therapy will receive escalating oral doses of RO5045377 and cytarabine 20 mg/m2
      subcutaneously daily for Days 1 to 10 of each 28-day cycle. In Arm B, cohorts of patients who
      have relapsed or are refractory after at least one cytarabine/anthracycline containing
      regimen will receive escalating oral doses of RO5045377 on Days 1 to 5 and cytarabine 1 gm/m2
      intravenously on Days 1 to 6 of each 28-day cycle. Patients will receive up to 4 cycles of
      therapy, patients in Arm A who achieve hematologic response may continue additional cycles
      until disease progression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose/dose-limiting toxicities</measure>
    <time_frame>approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Hematologic response</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Biomarkers (MIC-1, protein, nucleic acid, other) from bone marrow/buccal tissue/blood</measure>
    <time_frame>Pre-dose (and up to 12 hours post-dose Day 1 and Day 10 or Day 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax/area under the concentration-time curve</measure>
    <time_frame>Pre-dose and up to 12 hours post-dose Day 1 and Day 10 or Day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Myelogenous Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>A: Previously untreated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Relapse/Refractory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5045377</intervention_name>
    <description>Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle</description>
    <arm_group_label>A: Previously untreated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5045377</intervention_name>
    <description>Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle</description>
    <arm_group_label>B: Relapse/Refractory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>20 mg/m2 sc, Days 1 to 10 of each 28-day cycle</description>
    <arm_group_label>A: Previously untreated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>1 gm/m2 iv, Days 1 to 6 of each 28-day cycle</description>
    <arm_group_label>B: Relapse/Refractory</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Patients with histologically or cytologically documented acute myelogenous leukemia
             appropriate for cytarabine therapy including:

          -  Arm A: Patients who have not received prior standard induction chemotherapy,
             considered unsuitable for standard induction therapy

          -  Arm B: Patients who have failed their 1st or greater line of standard induction
             chemotherapy (primary refractory) or patients who originally achieved a complete
             response but are currently in first or greater relapse

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  All non-hematological adverse events of any prior chemotherapy, surgery, or
             radiotherapy must have resolved to NCI-CTC AE Grade &lt;/=2

          -  Adequate hepatic and renal function

          -  Patient must be willing to submit the blood sampling and bone marrow sampling for PK
             and PD analyses and exploratory biomarkers

        Exclusion Criteria:

          -  History of allergic or toxic reactions attributed to cytarabine or a history of
             allergic reactions to components of the formulated product

          -  Current evidence of CNS leukemia

          -  Any severe and/or uncontrolled medical condition or other conditions that could affect
             the participation in the study

          -  Pregnant or breastfeeding women

          -  HIV-positive patients receiving combination anti-retroviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M204BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

